Press Releases

3/9/2010 Javelin Pharmaceuticals Reports Fiscal Results for the Year Ended 2009	20.0 KB
2/17/2010 Javelin Pharmaceuticals' Receives FDA PDUFA Date for Dyloject(TM) NDA	12.7 KB
2/11/2010 Third Party Reexamination of Javelin Pharmaceuticals' Phase III Trial Data for Ereska (Intranasal Ketamine) Yields Statistically Significant Primary Endpoint	16.1 KB
2/2/2010 FDA Accepts Javelin Pharmaceuticals' Dyloject(TM) New Drug Application for Formal Review	14.9 KB
12/18/2009 Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals	23.5 KB
12/2/2009 Javelin Pharmaceuticals Submits Dyloject(TM) New Drug Application to FDA for Management of Acute Moderate-to-Severe Pain in Adults	10.9 KB
11/10/2009 Javelin Pharmaceuticals, Inc. Reports Third Quarter 2009 Results	15.3 KB
11/4/2009 Javelin Pharmaceuticals to Announce Third Quarter 2009 Financial Results	8.4 KB
10/30/2009 Javelin Pharmaceuticals, Inc. Tops Up Balance Sheet Through Registered Direct Offering	8.0 KB
8/11/2009 Javelin Pharmaceuticals Reports Ereska (Intranasal Ketamine) Phase III Trial Results in Postoperative Orthopedic Pain	10.6 KB
8/11/2009 Javelin Pharmaceuticals, Inc. Reports Second Quarter 2009 Results and Corporate Highlights	15.3 KB
8/4/2009 Javelin Pharmaceuticals to Host Second Quarter 2009 Conference Call	8.4 KB
6/23/2009 Javelin Pharmaceuticals Completes Open Label Safety Study of Dyloject(TM) -	10.4 KB
6/15/2009 New Study Shows Javelin Pharmaceutical's DylojectTM Well-Tolerated in High-Risk Patients with Impaired Renal and Hepatic Function	9.4 KB
5/7/2009 Javelin Pharmaceuticals, Inc. Reports First Quarter 2009 Results and Corporate Highlights	14.0 KB
5/4/2009 Javelin Pharmaceuticals to Announce First Quarter 2009 Financial Results	8.3 KB
3/12/2009 Javelin Pharmaceuticals Reports Fiscal Results for the Year Ended 2008	14.1 KB
3/5/2009 Javelin Pharmaceuticals Quarterly Conference Call Invitation	8.3 KB
1/15/2009 Javelin Pharmaceuticals Signs $71 million European Commercialization Partnership for Dyloject(R)	10.0 KB
1/8/2009 Javelin Pharmaceuticals CEO Martin J. Driscoll to Present at J.P. Morgan's 27th Annual Healthcare Conference	8.1 KB
Showing 1-20 of 143 releases Page: 1 2 3 4 5 6 7 8  See Next 20

CONTACT US   JOIN US   SITE MAP
© 2010 Javelin Pharmaceuticals,Inc. / Intrac,Inc. / IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.